CPRX Fail-to-Deliver

Catalyst Pharmaceuticals, Inc. (CPRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $3.81B, listed on NASDAQ, employing roughly 181 people, carrying a beta of 0.72 to the broader market. Catalyst Pharmaceuticals, Inc. Led by Richard John Daly, public since 2006-11-08.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-04-30
Latest FTD Quantity
98.8K
Latest Price
$28.26
30-Day Avg FTD
21.7K
30-Day Total FTD
649.9K

Showing 30 days of SEC fail-to-deliver data for Catalyst Pharmaceuticals, Inc..

Learn how fails-to-deliver is reported and how to read the data →

CPRX most-active contracts

TypeStrikeExpirationVolumeOIIVBidAsk
CALL$35.00Dec 18, 20264051.8K909.8%$0.05$0.15
CALL$30.00Dec 18, 20263256226.8%$1.60$1.70

Top 2 contracts from the ORATS-sourced nightly scan; ranked by volume within the broader S&P 500/400/600 + ETF universe.

Frequently asked CPRX fail to deliver questions

What is the latest CPRX fail-to-deliver count?
As of Apr 30, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) fail-to-deliver quantity is 98.8K shares, with a 30-day average of 21.7K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do CPRX FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.